Associations Between Albuminuria and Clinical Outcomes in Patients with CKD with and Without Diabetes: New Insights from DAPA-CKD
Dominique van Mil(University Medical Center Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Anna Maria Langkilde(AstraZeneca (Sweden)), Meir Schechter(Reichman University), Niels Jongs(University Medical Center Groningen), Glenn M. Chertow(Stanford Health Care), David C. Wheeler(University College London), Ricardo Correa-Rotter(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Priya Vart(University Medical Center Groningen), Peter Rossing(Steno Diabetes Centers), Robert D. Toto(Southwestern Medical Center)
Cited by 0
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients
|Journal of the American Society of Nephrology|2005|3.4k
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
|Journal of the American Society of Nephrology|2004|2.7k